Novo Nordisk is now seriously beginning to dedicate time and resources to finding new treatment options within RNA and gene therapies, informs Senior Vice President of Global Research Technologies at Novo Nordisk Lars Fogh Iversen in a statement on Linkedin.
The company has decided to create a new technology area to focus on RNA and gene therapy, which will be anchored in the Global Research Technologies division.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.